Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Cocrystal Pharma, Inc. COCP NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
66/100
3/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Cocrystal Pharma, Inc. (COCP) is a Biotechnology company in the Healthcare sector, currently trading at $1.54. It has a SharesGrow Score of 62/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Valuation: COCP trades at a trailing Price-to-Earnings (P/E) of -1.9 (S&P 500 average ~25).

Net income is $9M (loss), growing at +35.3%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $2M against $6M equity (Debt-to-Equity (D/E) ratio 0.24, conservative). Current ratio is 3.68 (strong liquidity). Debt-to-assets is 15.5%. Total assets: $10M.

Analyst outlook: 1 / 1 analysts rate COCP as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 100/100 (Pass), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

COCP SharesGrow Score Overview

82/100
SharesGrow Score
Strong investment profile
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 100/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — COCP

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✓
GROWTH Pass
100/100
COCP: +0%/yr revenue is, +35.3%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet COCP: Debt-to-Equity (D/E) ratio 0.24 (conservative), Current ratio is 3.68 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
COCP: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 1 / 1 analysts rate COCP as buy (100%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.86-2.67
Volume291.66K
Avg Volume (30D)2.48M
Market Cap$15.78M
Beta (1Y)1.18
Share Statistics
EPS (TTM)-0.78
Shares Outstanding$11.29M
IPO Date2012-02-22
Employees11
CEOSam Lee
Financial Highlights & Ratios
EBITDA$-8.64M
Net Income$-8.83M
Operating Income$-9.02M
Total Cash$7.03M
Total Debt$1.51M
Net Debt$-5.52M
Total Assets$9.71M
Price / Earnings (P/E)-2
Analyst Forecast
Rating ConsensusBuy
Analysts Covering1
Buy 100% Hold 0% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS19188J4094

Price Chart

Track all markets on TradingView
COCP
Cocrystal Pharma, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
0.86 52WK RANGE 2.67

People Also View

IKNA
IKNA
Ikena Oncology, Inc.
$17.16
+1,152.55%
 CBIO
CBIO
Catalyst Biosciences, Inc.
$19.95
+2.20%
 RNXT
RNXT
RenovoRx, Inc.
$1.02
-0.97%
 ONTX
ONTX
Onconova Therapeutics, Inc.
$1.00
-0.47%
 ALLR
ALLR
Allarity Therapeutics, Inc.
$1.25
+5.04%
 CYCC
CYCC
Cyclacel Pharmaceuticals, Inc.
$6.37
-5.98%
 TPST
TPST
Tempest Therapeutics, Inc.
$2.12
-5.57%
 ZIVO
ZIVO
ZIVO Bioscience, Inc.
$2.23
+5.19%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message